Bile duct cancer research

Bile duct cancer or cholangiocarcinoma is a type of primary liver cancer. It occurs when the cells of the ducts inside the liver that carry bile from the liver to the gallbladder or intestines are altered.

Although it is a rare cancer, more cases are diagnosed every year. It is a rare disease that is usually detected in advanced stages, when conventional treatment is not effective.

For this reason, research is key to improving the survival and quality of life of patients.

Need more information?

If you are interested in learning more about our research, please contact us.
 

We dream of curing cholangiocarcinoma

Research is needed to discover mechanisms for early detection of the disease and to optimize treatments.

We seek to know the genetic alterations that cause the appearance and development of conlangiocarcinoma.

Identify biomarkers for early diagnosis, prognosis and prediction of response to treatment.

Validate potential antitumor therapeutic targets and design new therapeutic therapies that reach patients as soon as possible.

REFERENCES IN BASIC AND TRANSLATIONAL RESEARCH

Research programs in Hepatology and Solid Tumors

The study of biliary tract cancer is addressed in two research programs at Cima: the Hepatology Program and the Solid Tumors Program.

Both programs have recognized expertise in preclinical research on this disease. Their common goal is to develop innovative anti-tumor therapies and validate early detection markers.

Diagnostic and therapeutic research

All our professionals and technical resources at the service of cholangiocarcinoma research

Genomics Platform

Our Genomics platform has state-of-the-art equipment for rapid and accurate sequencing of the genetic material of tumors.

Animal Production and Experimentation

Research support technology platform that supports researchers in HPB tumors through its management of animal models for research.

Platform
Image

Microscopy service and non-invasive imaging techniques ideal for the analysis of tumor evolution in preclinical models.